3 Absurdly Cheap Dividend Stocks to Buy in April 2026

Three dividend-focused stocks yield 3.4%–5.8% and trade at low forward P/Es (AbbVie 14, Novo Nordisk 11, Verizon 10). AbbVie is down ~10% YTD with a ~$370B market cap, reported $61.2B revenue and $20.1B operating income (33% margin) and yields ~3.4%. Novo Nordisk is down ~28% YTD with guidance for revenue to fall up to 13%, a four-quarter operating margin of ~41% and a 4.9% yield. Verizon yields ~5.8%, has a payout ratio around 50%, is up ~20% YTD, and cited better-than-expected guidance and strong recent wireless growth.

Analysis

Market reaction has created a valuation wedge where durable cash-generators with visible payout mechanics are trading on short-term operating noise; that disconnect magnifies optionality in a low-growth, high-yield regime. With forward P/Es in the low-teens, a 10–25% price re-rating is conservative if 12-month guidance and FCF beats the current consensus, while the dividend cushions drawdowns by ~3–6% annually versus growth names.

Second-order dynamics differ by company: AbbVie’s GAAP volatility from deal accounting masks free-cash-flow-driven capital returns and makes buyback pacing the marginal use of cash — if Humira/biosimilar headwinds accelerate, management is incentivized to reallocate from M&A to buybacks/dividend, compressing long-term growth but stabilizing yield. Novo Nordisk’s pricing shock forces operating leverage to be reoptimised: supply-chain contractors and CMO capacity will see utilisation swings, and FX/price-regulation vectors in key markets create asymmetric downside to near-term revenues but limited margin collapse given current >35% operating margins.

Verizon is the highest-conviction defensive equity: operational momentum in wireless creates a clear path for modest multiple expansion if net-adds and enterprise 5G monetisation continue; downside is capex normalization or churn elasticity if promotional pricing increases. Key catalysts across all three are next 2–4 quarterly guidances, regulatory decisions on drug pricing/biosimilars over 6–18 months, and macro rates which compress dividend-stock multiples quickly within 30–90 days.

Key Decisions for Investors

• Long ABBV (12-month target): buy shares sized to 2–3% of portfolio. Rationale: 14x forward P/E + 3.4% yield implies ~15–25% upside if guidance/FCF modestly beats. Risk control: buy 9–12 month puts (10–15% OTM) as protection or size stop-loss at 12% drawdown — downside scenario -12% if biosimilar pressure accelerates.
• Long VZ (6–12 months, dividend capture + multiple expansion): initiate position to 3–4% of portfolio; sell 3–6 month covered calls at 5–7% OTM to finance carry. Reward: ~20% price upside + 5.8% yield if wireless trends persist; risk: -15% if net-add momentum reverses — close on next two quarterly net-add prints if sequential improvement stalls.
• Directional NVO with defined-risk options (9–18 months): buy a bull-call spread or buy shares with a protective put to express recovery while limiting capital at risk. Expect asymmetric payoff: +30% recovery on normalization vs -30% on sustained revenue deterioration; cap exposure to 1–2% of portfolio given regulatory/competitive tail risk.
• Tactical pair (defensive skew): overweight ABBV + VZ vs underweight broad growth allocation (reduce exposure to high-beta names sized to offset notional). Time horizon 3–12 months to benefit from yield-floor and potential multiple compression reversal; monitor rates — if 10y>4.0% cut positions by 50%.